Intellia Therapeutics, Inc. (NTLA)

22,50 +1,10 (+5,14 %) À la clôture : 04:00PM EDT

Intellia Therapeutics, Inc.

40 Erie Street
Suite 130
Cambridge, MA 02139
United States
857 285 6200
https://www.intelliatx.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 526

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. John M. Leonard M.D.	President, CEO & Director	1,06M	S.O.	1957
Mr. Glenn G. Goddard CPA	Executive VP, CFO & Treasurer	630,91k	S.O.	1971
Dr. Laura Sepp-Lorenzino Ph.D.	Executive VP & Chief Scientific Officer	670,58k	S.O.	1961
Mr. James E. Basta Esq., J.D.	Executive VP, General Counsel & Corporate Secretary	616,15k	S.O.	1966
Dr. David Lebwohl M.D.	Executive VP & Chief Medical Officer	671,42k	S.O.	1955
Mr. Derek Hicks	Executive VP & Chief Business Officer	823,42k	S.O.	1974
Mr. Nessan Bermingham Ph.D.	Founder & Member of Scientific Advisor Board	1,38M	S.O.	1973
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder	S.O.	S.O.	1986
Dr. Andrew May Ph.D.	Founder and Member of Scientific Advisor Board	S.O.	S.O.	S.O.
Dr. Jennifer A. Doudna Ph.D.	Founder & Member of Scientific Advisor Board	S.O.	S.O.	1964

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Intellia Therapeutics, Inc. en date du 29 avril 2024 est 6. Les scores principaux sont Audit : 5; Société : 7; Droits des actionnaires : 8; Compensation : 5.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.